Is it time to move beyond the "O" in early COPD?
David M Mannino, Barry J Make
https://pubmed.ncbi.nlm.nih.gov/26621878/Actively Recruiting
Led by Gelb, Arthur F., M.D. · Updated on 2023-10-27
60
Participants Needed
2
Research Sites
47 weeks
Total Duration
Researchers are investigating the site and mechanisms responsible for expiratory airflow limitation in people who have chronic obstructive pulmonary disease COPD, emphysema, or asthma-COPD overlap. The study focuses on current or former smokers with a history of more than 15 pack years who have mild to severe expiratory airflow limitation. It aims to understand whether airflow limitation is due to problems in large central airways, small peripheral airways, loss of lung elastic recoil, or a combination of these factors. Participants will undergo extensive lung function tests including spirometry before and after inhaled bronchodilation, lung volume measurements, diffusing capacity, and lung elasticity assessment involving an esophageal balloon. Imaging studies include high-resolution CT scans of the lungs to measure emphysema and bronchiectasis. Blood tests and possibly bronchoscopy may also be performed to gather additional information. The study groups are categorized based on clinical, pathologic, laboratory, physiological, and radiological differences. During the study, participants will have assessments including lung function tests, blood tests, exhaled nitric oxide measurement, and imaging scans. Some tests may be uncomfortable but are expected to cause no harm. The primary measurement is to identify the site and mechanisms of expiratory airflow limitation over a four-year period. The study started in 2017 and is planned to continue through 2027, with participant involvement varying depending on the tests performed.
CONDITIONS
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
A
Arthur F Gelb, MD
C
Christine Fraser
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Gelb, Arthur F., M.D.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single assessment period
Participants undergo detailed lung function tests, blood studies, CT scans, and possibly bronchoscopy to determine the site and mechanism of expiratory airflow limitation.
1 to 2 visits depending on tests required
Duration - Up to 4 years
Participants are monitored over time to observe the progression and characteristics of expiratory airflow limitation and emphysema.
Periodic visits as scheduled by the study team
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
David M Mannino, Barry J Make
https://pubmed.ncbi.nlm.nih.gov/26621878/Carlos H Martinez, Alejandro A Diaz, Catherine Meldrum...
https://pubmed.ncbi.nlm.nih.gov/27564413/A F Gelb, M Schein, J Kuei...
https://pubmed.ncbi.nlm.nih.gov/8484625/Arthur F Gelb, Alfred Yamamoto, Thais Mauad...
https://pubmed.ncbi.nlm.nih.gov/24290280/Arthur F Gelb, Alfred Yamamoto, Eric K Verbeken...
https://pubmed.ncbi.nlm.nih.gov/25950858/Prescott G Woodruff, R Graham Barr, Eugene Bleecker...
https://pubmed.ncbi.nlm.nih.gov/27168432/Arthur F Gelb, Alfred Yamamoto, Eric K Verbeken...
https://pubmed.ncbi.nlm.nih.gov/29197547/A F Gelb, J C Hogg, N L Müller...
https://pubmed.ncbi.nlm.nih.gov/8620705/Stephen I Rennard, M Bradley Drummond
https://pubmed.ncbi.nlm.nih.gov/25943942/David P Johns, Julia A E Walters, E Haydn Walters
https://pubmed.ncbi.nlm.nih.gov/25478197/Gelb, Arthur F., M.D.
Lead Sponsor